BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc.:
Clinical stage company utilizing AI technology platform to identify improved therapies in neuroscience and immuno-oncology. BXCL501 (sublingual dexmedetomidine): Met primary, key secondary and exploratory endpoints in two pivotal Phase 3 trials for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). NDA submission to FDA planned 1Q21; Phase 1b/2 trial (TRANQUILITY) ongoing for the acute treatment of agitation associated with geriatric dementia. Data expected 4Q20; BXCL701 (innate immunity activator): Phase 1b/2 ongoing of BXCL701 and KEYTRUDA for Prostate Cancer (tNEPC).
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - New England
Clinical Stage
Phase III, Phase l or ll
Disease Space
Central Nervous System, Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
1B +
Therapeutic Modalities
Platform Technology, Small Molecule
Website:
Address:
555 Long Wharf Drive
5th Floor
New Haven, CT 06511
United States
5th Floor
New Haven, CT 06511
United States
More info:
My account:
Company Participants at Solebury Trout Corporate Access 1x1 Calls - Week of April 13
- Vimal Mehta, Dr, CEO
Top 10 Holders of BioXcel Therapeutics, Inc.
| Institution | OS (%) | Position | Mkt Val ($MM) | Source | Filing Date |
|---|---|---|---|---|---|
| Fidelity Management & Research Co. LLC | 10.65 | 1,919,986 | 101.01 | 13F | 9/30/20 |
| State Street Corp. | 7.17 | 1,293,856 | 68.07 | 13F | 9/30/20 |
| Artemis Investment Management LLP | 5.55 | 1,001,708 | 52.70 | 13F | 9/30/20 |
| DNCA Finance SA | 3.66 | 892,453 | 46.95 | Stakes | 3/3/20 |
| Vanguard Group, Inc. (Subfiler) | 4.60 | 829,760 | 43.65 | 13F | 9/30/20 |
| The Vanguard Group, Inc. | 4.15 | 753,588 | 39.65 | Funds | 11/30/20 |
| Citadel LP | 4.16 | 749,621 | 39.44 | 13F | 9/30/20 |
| Victory Capital Management, Inc. (Investment Management) | 3.30 | 594,294 | 31.27 | 13F | 9/30/20 |
| AllianceBernstein LP | 3.27 | 590,285 | 31.05 | 13F | 9/30/20 |
| Logos Global Management LP | 3.05 | 550,000 | 28.94 | 13F | 9/30/20 |
Ownership data is sourced through FactSet.
Stock Market Data
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia.
Data delayed 15 minutes unless otherwise indicated (view
delay times for all
exchanges). RT=Real-Time, RTB=Real-Time
BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time
NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of
Day, PD=Previous Day. Market Data powered by
QuoteMedia.
Terms of Use.